Ionis Pharmaceuticals (IONS) Stock Forecast, Price Target & Predictions
IONS Stock Forecast
Ionis Pharmaceuticals stock forecast is as follows: an average price target of $51.68 (represents a 34.44% upside from IONS’s last price of $38.44) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.
IONS Price Target
The average price target for Ionis Pharmaceuticals (IONS) is $51.68 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $77.00 to $28.00. This represents a potential 34.44% upside from IONS's last price of $38.44.
IONS Analyst Ratings
According to 18 Wall Street analysts, Ionis Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for IONS stock is 0 'Strong Buy' (0.00%), 9 'Buy' (50.00%), 8 'Hold' (44.44%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).
Ionis Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 09, 2024 | Debjit Chattopadhyay | Guggenheim | $65.00 | $37.80 | 71.96% | 69.09% |
| Aug 02, 2024 | Kostas Biliouris | BMO Capital | $60.00 | $51.32 | 16.91% | 56.09% |
| Jul 24, 2024 | Mani Foroohar | Leerink Partners | $62.00 | $51.86 | 19.55% | 61.29% |
| Jul 22, 2024 | Akash Tewari | Jefferies | $77.00 | $50.61 | 52.14% | 100.31% |
| Jul 22, 2024 | Salveen Richter | Goldman Sachs | $33.00 | $50.61 | -34.80% | -14.15% |
| Jul 16, 2024 | Akash Tewari | Jefferies | $75.00 | $49.84 | 50.48% | 95.11% |
| Jun 27, 2024 | Paul Matteis | Stifel Nicolaus | $53.00 | $47.70 | 11.11% | 37.88% |
| Jun 17, 2024 | Luca Issi | RBC Capital | $70.00 | $40.63 | 72.29% | 82.10% |
| Jun 14, 2024 | William Pickering | Tudor Pickering | $44.00 | $41.12 | 7.00% | 14.46% |
| May 17, 2024 | Kostas Biliouris | BMO Capital | $67.00 | $36.84 | 81.87% | 74.30% |
The latest Ionis Pharmaceuticals stock forecast, released on Oct 09, 2024 by Debjit Chattopadhyay from Guggenheim, set a price target of $65.00, which represents a 71.96% increase from the stock price at the time of the forecast ($37.80), and a 69.09% increase from IONS last price ($38.44).
Ionis Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 10 |
| Avg Price Target | $65.00 | $65.00 | $60.60 |
| Last Closing Price | $38.44 | $38.44 | $38.44 |
| Upside/Downside | 69.09% | 69.09% | 57.65% |
In the current month, the average price target of Ionis Pharmaceuticals stock is $65.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 69.09% increase as opposed to Ionis Pharmaceuticals's last price of $38.44. This month's average price target is down 0.00% compared to last quarter, and up 7.26% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 09, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 26, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
| Sep 26, 2024 | Needham | Underperform | Underperform | Hold |
| Aug 26, 2024 | Needham | Market Perform | Market Perform | Hold |
| Aug 02, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Aug 02, 2024 | BMO Capital | Outperform | Market Perform | Downgrade |
| Jul 24, 2024 | Leerink Partners | - | Outperform | Upgrade |
| Jul 22, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 22, 2024 | William Blair | Outperform | Outperform | Hold |
| Jul 22, 2024 | Goldman Sachs | Sell | Sell | Hold |
Ionis Pharmaceuticals's last stock rating was published by Guggenheim on Oct 09, 2024. The company gave IONS a "Buy" rating, the same as its previous rate.
Ionis Pharmaceuticals Financial Forecast
Ionis Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $144.21M | $188.41M | $131.00M | $152.00M | $159.77M | $133.79M | $141.92M | $440.01M | $133.09M | $125.75M | $111.61M | $290.28M | $160.08M | $145.54M | $133.37M | $493.68M | $167.89M | $163.81M | $297.21M | $144.42M | $110.30M |
| Avg Forecast | $208.74M | $176.48M | $155.08M | $135.99M | $146.75M | $129.32M | $156.09M | $131.42M | $174.12M | $136.86M | $140.44M | $128.15M | $160.13M | $143.95M | $140.54M | $122.46M | $275.55M | $160.15M | $129.16M | $128.62M | $274.46M | $182.14M | $148.87M | $161.13M | $407.05M | $153.80M | $145.31M | $285.38M | $433.26M | $183.84M |
| High Forecast | $208.74M | $176.48M | $155.08M | $135.99M | $146.75M | $147.90M | $157.96M | $131.42M | $207.03M | $166.52M | $140.44M | $128.15M | $160.13M | $143.95M | $140.54M | $122.46M | $275.55M | $160.15M | $129.16M | $128.62M | $274.46M | $182.14M | $148.87M | $161.13M | $407.05M | $153.80M | $145.31M | $285.38M | $519.91M | $220.61M |
| Low Forecast | $208.74M | $176.48M | $155.08M | $135.99M | $146.75M | $113.82M | $154.22M | $131.42M | $128.03M | $121.42M | $140.44M | $128.15M | $160.13M | $143.95M | $140.54M | $122.46M | $275.55M | $160.15M | $129.16M | $128.62M | $274.46M | $182.14M | $148.87M | $161.13M | $407.05M | $153.80M | $145.31M | $285.38M | $346.61M | $147.07M |
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.05% | 1.34% | 1.02% | 0.95% | 1.11% | 0.95% | 1.16% | 1.60% | 0.83% | 0.97% | 0.87% | 1.06% | 0.88% | 0.98% | 0.83% | 1.21% | 1.09% | 1.13% | 1.04% | 0.33% | 0.60% |
Ionis Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 9 analysts is $174.12M, with a low forecast of $128.03M, and a high forecast of $207.03M. IONS's average Quarter revenue forecast represents a 20.75% increase compared to the company's last Quarter revenue of $144.21M (Sep 23).
Ionis Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-143.26M | $-90.19M | $-97.00M | $-358.00M | $-50.69M | $-94.06M | $-53.74M | $227.09M | $-76.73M | $-73.18M | $-83.38M | $-6.42M | $-12.52M | $-17.08M | $-36.38M | $236.16M | $26.93M | $8.69M | $130.63M | $12.34M | $17.20M |
| Avg Forecast | $-54.34M | $-45.94M | $-40.37M | $-35.40M | $-38.20M | $-33.66M | $-40.63M | $-109.83M | $-45.33M | $-35.63M | $-36.56M | $-99.85M | $-41.68M | $-37.47M | $-36.58M | $-78.93M | $-71.73M | $-41.69M | $-33.62M | $-64.14M | $-71.44M | $-47.41M | $-38.75M | $-33.35M | $-105.96M | $-40.03M | $-37.83M | $123.99M | $18.51M | $21.68M |
| High Forecast | $-54.34M | $-45.94M | $-40.37M | $-35.40M | $-38.20M | $-29.63M | $-40.14M | $-87.87M | $-33.33M | $-31.61M | $-36.56M | $-79.88M | $-41.68M | $-37.47M | $-36.58M | $-63.14M | $-71.73M | $-41.69M | $-33.62M | $-51.31M | $-71.44M | $-47.41M | $-38.75M | $-26.68M | $-105.96M | $-40.03M | $-37.83M | $148.79M | $22.21M | $26.01M |
| Low Forecast | $-54.34M | $-45.94M | $-40.37M | $-35.40M | $-38.20M | $-38.50M | $-41.12M | $-131.80M | $-53.89M | $-43.35M | $-36.56M | $-119.82M | $-41.68M | $-37.47M | $-36.58M | $-94.72M | $-71.73M | $-41.69M | $-33.62M | $-76.97M | $-71.44M | $-47.41M | $-38.75M | $-40.02M | $-105.96M | $-40.03M | $-37.83M | $99.19M | $14.81M | $17.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | 4.02% | 2.47% | 0.97% | 8.59% | 1.35% | 2.57% | 0.68% | -3.17% | 1.84% | 2.18% | 1.30% | 0.09% | 0.26% | 0.44% | 1.09% | -2.23% | -0.67% | -0.23% | 1.05% | 0.67% | 0.79% |
13 analysts predict IONS's average Quarter EBITDA for Mar 22 to be $-78.93M, with a high of $-63.14M and a low of $-94.72M. This is -134.76% lower than Ionis Pharmaceuticals's previous annual EBITDA (Dec 21) of $227.09M.
Ionis Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-147.41M | $-85.29M | $-124.00M | $-52.00M | $-46.99M | $-105.14M | $-65.17M | $224.61M | $-82.47M | $-80.88M | $-89.87M | $-340.27M | $-30.94M | $-31.84M | $-48.23M | $184.42M | $26.16M | $-876.00K | $84.44M | $-1.42M | $3.47M |
| Avg Forecast | $-135.49M | $-149.05M | $-161.52M | $-170.23M | $-160.49M | $-164.26M | $-135.02M | $-122.61M | $-117.30M | $-147.17M | $-128.88M | $-111.46M | $573.79M | $-105.57M | $-89.04M | $-88.11M | $-6.38M | $-71.16M | $-80.98M | $-69.13M | $37.77M | $-18.93M | $-37.73M | $-44.21M | $140.04M | $-44.37M | $-40.14M | $80.15M | $-2.13M | $4.37M |
| High Forecast | $-135.49M | $-149.05M | $-161.52M | $-170.23M | $-160.49M | $-131.97M | $-135.02M | $-98.08M | $-42.11M | $-101.78M | $-128.88M | $-89.17M | $688.54M | $-105.57M | $-89.04M | $-70.49M | $-6.38M | $-71.16M | $-80.98M | $-55.30M | $37.77M | $-18.93M | $-37.73M | $-35.37M | $140.04M | $-44.37M | $-40.14M | $96.18M | $-1.70M | $5.24M |
| Low Forecast | $-135.49M | $-149.05M | $-161.52M | $-170.23M | $-160.49M | $-183.92M | $-135.02M | $-147.13M | $-172.94M | $-171.93M | $-128.88M | $-133.75M | $459.03M | $-105.57M | $-89.04M | $-105.73M | $-6.38M | $-71.16M | $-80.98M | $-82.96M | $37.77M | $-18.93M | $-37.73M | $-53.05M | $140.04M | $-44.37M | $-40.14M | $64.12M | $-2.56M | $3.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 0.66% | 1.11% | -0.09% | 0.45% | 1.18% | 0.74% | -35.23% | 1.16% | 1.00% | 1.30% | -9.01% | 1.63% | 0.84% | 1.09% | 1.32% | -0.59% | 0.02% | 1.05% | 0.67% | 0.79% |
Ionis Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-88.11M, with a range of $-105.73M to $-70.49M. IONS's average Quarter net income forecast represents a -139.23% decrease compared to the company's last Quarter net income of $224.61M (Dec 21).
Ionis Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $69.95M | $46.14M | $46.00M | $48.00M | $34.40M | $33.80M | $34.10M | $38.60M | $30.10M | $45.10M | $57.10M | $138.84M | $68.45M | $72.02M | $74.99M | $83.28M | $60.04M | $75.11M | $68.22M | $43.65M | $13.68M |
| Avg Forecast | $63.60M | $53.77M | $47.25M | $41.43M | $44.71M | $39.40M | $47.56M | $64.16M | $53.05M | $41.70M | $42.79M | $58.33M | $98.61M | $43.86M | $42.82M | $46.11M | $83.95M | $48.79M | $39.35M | $43.92M | $83.62M | $55.49M | $45.36M | $68.74M | $124.02M | $46.86M | $44.27M | $64.75M | $65.48M | $17.23M |
| High Forecast | $63.60M | $53.77M | $47.25M | $41.43M | $44.71M | $45.06M | $48.13M | $76.99M | $63.08M | $50.73M | $42.79M | $69.99M | $118.33M | $43.86M | $42.82M | $55.33M | $83.95M | $48.79M | $39.35M | $52.71M | $83.62M | $55.49M | $45.36M | $82.49M | $124.02M | $46.86M | $44.27M | $77.70M | $78.58M | $20.68M |
| Low Forecast | $63.60M | $53.77M | $47.25M | $41.43M | $44.71M | $34.68M | $46.99M | $51.33M | $39.01M | $36.99M | $42.79M | $46.66M | $78.88M | $43.86M | $42.82M | $36.89M | $83.95M | $48.79M | $39.35M | $35.14M | $83.62M | $55.49M | $45.36M | $55.00M | $124.02M | $46.86M | $44.27M | $51.80M | $52.38M | $13.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.68% | 1.08% | 0.79% | 0.49% | 0.78% | 0.79% | 0.74% | 0.46% | 0.62% | 1.15% | 1.30% | 1.66% | 1.23% | 1.59% | 1.09% | 0.67% | 1.28% | 1.70% | 1.05% | 0.67% | 0.79% |
Ionis Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $53.05M, based on 9 Wall Street analysts, with a range of $39.01M to $63.08M. The forecast indicates a -24.16% fall compared to IONS last annual SG&A of $69.95M (Sep 23).
Ionis Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.03 | $-0.60 | $-0.87 | $-0.37 | $-0.33 | $-0.74 | $-0.46 | $1.59 | $-0.58 | $-0.57 | $-0.64 | $-2.44 | $-0.22 | $-0.23 | $-0.35 | $1.31 | $0.19 | $-0.01 | $0.63 | $-0.01 | $0.03 |
| Avg Forecast | $-0.93 | $-1.02 | $-1.11 | $-1.17 | $-1.10 | $-1.13 | $-0.93 | $-1.03 | $-0.80 | $-1.01 | $-0.88 | $-0.87 | $-0.94 | $-0.72 | $-0.61 | $-0.69 | $-0.04 | $-0.49 | $-0.55 | $-0.51 | $0.26 | $-0.13 | $-0.26 | $-0.14 | $0.96 | $-0.30 | $-0.28 | $0.61 | $-0.05 | $0.06 |
| High Forecast | $-0.93 | $-1.02 | $-1.11 | $-1.17 | $-1.10 | $-0.90 | $-0.93 | $-1.03 | $-0.29 | $-0.70 | $-0.88 | $-0.87 | $-0.94 | $-0.72 | $-0.61 | $-0.69 | $-0.04 | $-0.49 | $-0.55 | $-0.51 | $0.26 | $-0.13 | $-0.26 | $-0.14 | $0.96 | $-0.30 | $-0.28 | $0.61 | $-0.04 | $0.08 |
| Low Forecast | $-0.93 | $-1.02 | $-1.11 | $-1.17 | $-1.10 | $-1.26 | $-0.93 | $-1.03 | $-1.18 | $-1.18 | $-0.88 | $-0.87 | $-0.94 | $-0.72 | $-0.61 | $-0.69 | $-0.04 | $-0.49 | $-0.55 | $-0.51 | $0.26 | $-0.13 | $-0.26 | $-0.14 | $0.96 | $-0.30 | $-0.28 | $0.61 | $-0.05 | $0.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 0.68% | 1.00% | 0.39% | 0.46% | 1.21% | 0.67% | -36.40% | 1.19% | 1.03% | 1.26% | -9.43% | 1.70% | 0.89% | 2.58% | 1.37% | -0.63% | 0.04% | 1.04% | 0.20% | 0.50% |
According to 13 Wall Street analysts, Ionis Pharmaceuticals's projected average Quarter EPS for Mar 22 is $-0.69, with a low estimate of $-0.69 and a high estimate of $-0.69. This represents a -143.22% decrease compared to IONS previous annual EPS of $1.59 (Dec 21).
Ionis Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $20.06 | $45.38 | 126.22% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| IOVA | Iovance Biotherapeutics | $11.44 | $21.00 | 83.57% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| BMRN | BioMarin Pharmaceutical | $66.01 | $101.70 | 54.07% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| SRPT | Sarepta Therapeutics | $123.07 | $169.63 | 37.83% | Buy |
| IONS | Ionis Pharmaceuticals | $38.44 | $51.68 | 34.44% | Buy |
| PTCT | PTC Therapeutics | $40.39 | $46.50 | 15.13% | Hold |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| INCY | Incyte | $75.75 | $84.56 | 11.63% | Buy |
| HALO | Halozyme Therapeutics | $58.47 | $56.86 | -2.75% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| ALNY | Alnylam Pharmaceuticals | $269.95 | $254.21 | -5.83% | Buy |
| EXEL | Exelixis | $34.29 | $30.50 | -11.05% | Buy |
IONS Forecast FAQ
Is Ionis Pharmaceuticals a good buy?
Yes, according to 18 Wall Street analysts, Ionis Pharmaceuticals (IONS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 50.00% of IONS's total ratings.
What is IONS's price target?
Ionis Pharmaceuticals (IONS) average price target is $51.68 with a range of $28 to $77, implying a 34.44% from its last price of $38.44. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ionis Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for IONS stock, the company can go up by 34.44% (from the last price of $38.44 to the average price target of $51.68), up by 100.31% based on the highest stock price target, and down by -27.16% based on the lowest stock price target.
Can Ionis Pharmaceuticals stock reach $60?
IONS's highest twelve months analyst stock price target of $77 supports the claim that Ionis Pharmaceuticals can reach $60 in the near future.
What is Ionis Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $65 price target for Ionis Pharmaceuticals (IONS) this month, up 69.09% from its last price of $38.44. Compared to the last 3 and 12 months, the average price target increased by 69.09% and increased by 57.65%, respectively.
What are Ionis Pharmaceuticals's analysts' financial forecasts?
Ionis Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $563.58M (high $584.03M, low $546.21M), average EBITDA is $-222M (high $-196M, low $-250M), average net income is $-582M (high $-526M, low $-627M), average SG&A $195.82M (high $214.89M, low $177.7M), and average EPS is $-4.183 (high $-3.962, low $-4.318). IONS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $676.29M (high $676.29M, low $676.29M), average EBITDA is $-176M (high $-176M, low $-176M), average net income is $-616M (high $-616M, low $-616M), average SG&A $206.05M (high $206.05M, low $206.05M), and average EPS is $-4.222 (high $-4.222, low $-4.222).
Did the IONS's actual financial results beat the analysts' financial forecasts?
Based on Ionis Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $587M, beating the average analysts forecast of $567.08M by 3.51%. Apple's EBITDA was $-561M, beating the average prediction of $-195M by 188.18%. The company's net income was $-270M, missing the average estimation of $291.06M by -192.77%. Apple's SG&A was $151M, missing the average forecast of $231.39M by -34.74%. Lastly, the company's EPS was $-1.9, missing the average prediction of $-2.96 by -35.82%. In terms of the last quarterly report (Sep 2023), Ionis Pharmaceuticals's revenue was $144.21M, beating the average analysts' forecast of $136.86M by 5.37%. The company's EBITDA was $-143M, beating the average prediction of $-35.626M by 302.13%. Ionis Pharmaceuticals's net income was $-147M, beating the average estimation of $-147M by 0.16%. The company's SG&A was $69.95M, beating the average forecast of $41.7M by 67.76%. Lastly, the company's EPS was $-1.03, beating the average prediction of $-1.008 by 2.15%